Peripartum
The peripartum period is an unusual corner of this field, because here the race for a fast-acting treatment has already been won, and not by psychedelics. Postpartum depression now has approved rapid-acting drugs, brexanolone and the oral pill zuranolone, but these are neurosteroids, a different class entirely. Classic psychedelics, meanwhile, are largely shut out of pregnancy and breastfeeding on safety grounds: the risks to a fetus or nursing infant are unknown, and a parent cannot be incapacitated for hours while caring for a newborn. The real psychedelic-adjacent activity is perioperative ketamine to prevent postpartum depression, where the evidence is genuine but mixed, and a newer effort to design ultra-short-acting psychedelics specifically for this window. It is early, complicated by real safety limits, and the most eye-catching result so far was uncontrolled.
How are psychedelics being studied in the peripartum period? The peripartum period, around pregnancy and the time after birth, includes conditions such as postnatal depression that can be serious and are sensitive to treatment choices. Psychedelic research here is cautious and early, because safety during pregnancy and breastfeeding is a major consideration and these groups are usually excluded from trials. Interest centres on postnatal depression once the safety questions can be addressed, drawing on the wider depression research. The evidence is very limited, and caution is the dominant theme. Blossom tracks any trials and papers in this area so you can follow the evidence.
Data updated
Key Insights
- 1
Peripartum is the rare indication where a fast-acting treatment already exists. Postpartum depression has FDA-approved rapid-acting medicines, brexanolone (2019) and the oral zuranolone (2023), but these are neurosteroids, not psychedelics, so the goal psychedelics pursue elsewhere has here been met by a different drug class.
- 2
Classic psychedelics are largely barred from the peripartum window. Pregnancy and breastfeeding are near-absolute exclusions: fetal and infant safety is unknown, the drugs can transfer to the baby, and a parent cannot safely be incapacitated for hours while solely caring for a newborn.
- 3
The main psychedelic-adjacent research is perioperative ketamine or esketamine, a single low dose around caesarean delivery, to prevent postpartum depression. A 2022 meta-analysis leans positive for short-term symptoms, but individual trials are mixed, including a clearly negative one, and breastfeeding cautions apply.
- 4
A genuinely new idea is to design ultra-short-acting psychedelics for this niche, where a brief experience would suit a postpartum parent. The most striking result, inhaled 5-MeO-DMT producing full remission in a small group, was open-label (ten people), and the company has since deprioritised the postpartum programme.
- 5
Postpartum mental illness is common and serious, and postpartum psychosis is a medical emergency. No classic psychedelic is approved or recommended for any peripartum condition, and self-treatment during pregnancy or breastfeeding is specifically unsafe.
By the numbers
- 18
- Trials tracked
- 8
- Papers tracked
- 2,886
- Trial participants
as of June 2026
as of June 2026
as of June 2026
What is Peripartum?
The peripartum period, spanning pregnancy and the months after birth, carries a high burden of mental illness. Postpartum depression affects roughly 1 in 7 mothers; anxiety, obsessive symptoms and, rarely, postpartum psychosis (a psychiatric emergency) also occur, and suicide is among the leading causes of maternal death. It is common, serious and frequently under-recognised and under-treated. Because the core problem is depression with a specific onset, this page sits within the depressive disorders family.
What makes peripartum distinctive in psychedelic research is a reversal of the usual story. Across most of this field, the prize is a fast-acting antidepressant for a hard-to-treat group, and psychedelics are the leading contenders. In postpartum depression, that prize has already been claimed, by a different class of drug. And the very features that make psychedelics promising elsewhere, long, intense, incapacitating experiences, are precisely what make them hard to use safely in someone who is pregnant or caring around the clock for an infant. So this is less a story of psychedelic promise than of psychedelics arriving late to a problem that is partly already being solved, and being held back by real safety limits.
Current Treatments
Standard care for peripartum depression combines psychological therapy with, where needed, antidepressants chosen for safety in pregnancy and breastfeeding, alongside practical and social support. What sets this condition apart is that it now also has dedicated rapid-acting drugs. Brexanolone, an intravenous neurosteroid, was approved in 2019 as the first medicine specifically for postpartum depression, and in 2023 zuranolone (Zurzuvae) became the first oral treatment approved for it, a 14-day course that can lift symptoms within days. Both are neurosteroids that act on the brain’s GABA system, not psychedelics.
Those approvals matter for how this page should be read. They mean the unmet need in postpartum depression, while real, is narrower than in conditions with no fast option: it now centres on people who do not respond to or cannot access these treatments (zuranolone is costly, causes sedation and carries its own breastfeeding cautions), and on the most severe presentations. Reviews weighing psychedelic therapy against this backdrop frame it as a possible future addition rather than a first move[1], and any psychedelic approach has to justify itself against treatments that already work quickly, not against a vacuum.
This report summarises what Blossom’s database shows about psychedelics and the peripartum period, and it is an unusual entry in this collection, because here the headline story is not really about psychedelics. Postpartum depression already has approved fast-acting drugs, they are neurosteroids rather than psychedelics, classic psychedelics are largely shut out by pregnancy and breastfeeding safety, and the genuine psychedelic-adjacent research, mostly perioperative ketamine, is promising but mixed. It is a field where psychedelics are a secondary, constrained and still-early player.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Peripartum mental illness is serious, postpartum psychosis is a medical emergency, and suicide is a leading cause of maternal death; if you are struggling, please seek help urgently. Crucially, no classic psychedelic is approved or recommended for any peripartum condition, and using one during pregnancy or breastfeeding is specifically unsafe: the risks to a developing baby or nursing infant are unknown, and being incapacitated while caring for a newborn is dangerous in itself. Effective, approved treatments for postpartum depression now exist, and they, with proper medical guidance, are where help should begin.
A word on scope and numbers. The trial count under this topic looks healthy, but it is dominated by studies of perioperative ketamine and esketamine, and of the approved neurosteroids, rather than by classic-psychedelic therapy. The genuinely psychedelic, postpartum-specific clinical evidence is tiny, effectively one small open-label study of a short-acting compound. Read the counts with that composition in mind.
The race that psychedelics did not win
In most of this field, the compelling pitch for psychedelics is speed: a single treatment that lifts depression in days rather than weeks, for people the slow conventional drugs have failed. Postpartum depression is the one place where that pitch has already been answered, by something else. Brexanolone, an intravenous neurosteroid, was approved in 2019 as the first drug specifically for postpartum depression, and in 2023 zuranolone became the first oral one, a short course that can work within days. Neither is a psychedelic; both act on the brain’s GABA system and reflect a distinct line of science about the hormone-derived neurosteroids that fall sharply after birth.
This changes the frame for everything that follows. A fast-acting antidepressant for this population is no longer a gap waiting to be filled; it is a treatment that exists, against which any newcomer must compete. Reviews that weigh psychedelics for postpartum depression do so explicitly in this light[1], positioning them as a possible future option for people the approved treatments do not reach, not as the obvious next breakthrough. It is a healthy reminder that psychedelics are one promising approach among several, not the only road to rapid relief.
Why classic psychedelics are mostly shut out
The second defining fact is a safety wall. Pregnancy and breastfeeding are among the firmest exclusion criteria in all of psychedelic research, for reasons that are not bureaucratic. The effects of psilocybin, MDMA or LSD on a developing fetus are essentially unstudied and potentially serious; the drugs can pass into breast milk; and, beyond the pharmacology, there is the plain practical danger of a parent being profoundly altered and incapacitated for many hours while solely responsible for a newborn. These are not problems that better trial design can wave away. They mean that, for much of the peripartum period, classic psychedelics are effectively off the table.
This is why the psychedelic research that does exist clusters at the edges of the period, or uses very different tools. It also explains why the most creative recent thinking has gone not into testing standard psychedelics in pregnancy, which would be hard to justify, but into changing the drugs themselves to fit the constraint.
The real activity: perioperative ketamine
The largest body of genuinely relevant evidence concerns ketamine and its enantiomer esketamine, used in a specific preventive way: a single low dose given around caesarean delivery, when the woman is already in hospital, to head off postpartum depression. A 2022 meta-analysis of these perioperative trials found that a single ketamine dose reduced short-term postpartum depression symptoms[2], and more recent caesarean-section studies of low-dose esketamine report similar early benefits[3]. As a preventive delivered at an opportune moment, it is a genuinely sensible idea.
But the evidence is mixed and shallow. A careful 2017 randomised trial found no preventive effect from a single ketamine bolus[4], the positive findings tend to be short-term, the trials are heterogeneous, and there are breastfeeding considerations whenever an anaesthetic-class drug is used around delivery. It is also worth being precise that this is prevention at the moment of birth, not treatment for a mother who becomes depressed weeks or months later, and that esketamine, despite the old page’s claim, is not approved for postpartum depression. The fair summary is a real, actively pursued preventive signal that has not yet been pinned down.
The clever idea, and a cautionary tale
The most interesting recent development confronts the duration problem directly. If the obstacle to using a psychedelic in a new parent is that it lasts hours, the answer might be one that lasts minutes. Inhaled 5-MeO-DMT, developed as GH001, produces a very short, very intense experience, and a Phase 2a study reported that all ten women with postpartum depression treated were in remission a week later[5]. On its face, a brief treatment producing complete remission is close to the ideal for this population.
The reasons for caution are instructive. The study had ten participants, no control group and no blinding, the precise conditions under which expectancy and natural recovery inflate apparent results, and a "100% remission" figure from such a design should be read as hypothesis-generating, not as proof. Most tellingly, the developer has since deprioritised its postpartum programme to concentrate on treatment-resistant depression, which is not what a company does with a confirmed breakthrough. A separate short-acting compound, RE104, remains at the early safety stage in healthy volunteers[6]. The short-acting concept is genuinely well-matched to the problem and deserves proper, controlled trials; what it does not yet have is evidence.
Reading this honestly
So where does the peripartum period sit? It is the clearest case in this field of psychedelics being a secondary, constrained option rather than a leading one. The fast-acting treatment that psychedelics promise elsewhere has, for postpartum depression, already arrived in the form of neurosteroids; classic psychedelics are largely and rightly excluded during pregnancy and breastfeeding; the real psychedelic-adjacent evidence, perioperative ketamine, is promising but unsettled; and the most exciting psychedelic-specific result is a tiny open-label study from a programme its own sponsor has stepped back from. The thoughtful reviews treat this as an area of genuine but distinctly future-tense possibility[7]. For new and expectant parents, the truthful and reassuring message is that effective, approved rapid treatments for postpartum depression now exist, that psychedelics are not currently among the safe or recommended options, and that any future role will have to be carved out carefully, within real limits, and only where the treatments that already work fall short.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Peripartum.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine The most-studied here, used perioperatively (a single low dose around caesarean delivery) to prevent postpartum depression. A 2022 meta-analysis suggests a reduction in short-term PPD symptoms, but individual RCTs are mixed, including a clearly negative trial, effects are short-term, and breastfeeding cautions apply. A real but unsettled preventive signal, not a treatment for established PPD. | Small | Low | Low |
| Esketamine Used in the same perioperative, PPD-prevention role as racemic ketamine, with several recent caesarean-section trials reporting reduced early depressive symptoms. Importantly, esketamine is NOT approved for postpartum depression (the approved drugs are neurosteroids). Promising for short-term prevention, mixed and modest, with the same breastfeeding considerations. | Small | Low | Low |
| 5-MeO-DMT The emerging idea of an ultra-short-acting psychedelic designed to suit a postpartum parent. Inhaled 5-MeO-DMT (GH001) produced full remission in a Phase 2a study, but in just ten people, open-label, and the developer has since deprioritised the postpartum programme. A related short-acting agent (RE104) is at an early stage. Striking design rationale, earliest and uncontrolled evidence. | Small | Very Low | Low |
Ketamine and Peripartum
Ketamine is the centre of the real peripartum research, and it is used in a specific, clever way: a single low (sub-anaesthetic) dose given around the time of caesarean delivery, to try to prevent postpartum depression before it takes hold. A 2022 meta-analysis of these perioperative trials concluded that a single ketamine dose can reduce postpartum depression symptoms in the short term[1], which is a genuine and appealing signal, especially as a preventive given at a moment when the woman is already in hospital.
The evidence is not clean, though. Individual trials disagree: a well-conducted 2017 randomised trial found that a single low-dose ketamine bolus did not prevent postpartum depression[2], and the positive studies tend to show short-term effects that may not last, in heterogeneous designs. There are also breastfeeding considerations with any anaesthetic-adjacent drug. So perioperative ketamine for postpartum depression is a real, actively studied idea with a plausible but mixed and short-term evidence base, not an established treatment, and it is prevention at delivery rather than therapy for someone already unwell weeks later.
Esketamine and Peripartum
Esketamine, the nasal-spray enantiomer of ketamine, is studied in the same perioperative, prevention-focused way, and several recent trials, mostly in women undergoing caesarean section, report that a single low dose of esketamine can improve early postpartum depression symptoms and recovery[1]. The signal mirrors the racemic-ketamine story: encouraging for short-term prevention, modest, and not yet settled.
One point needs emphasising, because the previous version of this page got it wrong. Esketamine is not approved for postpartum depression. It is approved (as Spravato) for treatment-resistant depression and for depression with acute suicidality, not for PPD, and the drugs actually approved for postpartum depression are the neurosteroids brexanolone and zuranolone. Presenting esketamine as an established, high-evidence postpartum treatment, as the old page did, overstates both its evidence and its regulatory status.
5-MeO-DMT and Peripartum
The most interesting recent idea tackles the central obstacle head-on: if the problem with classic psychedelics in postpartum care is that they incapacitate a parent for hours, why not use one that lasts minutes? Inhaled 5-MeO-DMT (developed as GH001) produces a brief, intense experience, and a Phase 2a study reported that all ten women with postpartum depression were in remission a week after treatment[1]. A headline of "100% remission" is exactly the kind of result that travels fast.
It should travel slowly. The study was open-label with no control group and just ten participants, the design in which expectancy produces the largest apparent effects, and, tellingly, the company has since deprioritised its postpartum programme in favour of treatment-resistant depression. A separate short-acting agent, RE104, is still at the early, healthy-volunteer safety stage[2]. The short-acting concept is genuinely well-suited to the postpartum problem and worth watching, but the current evidence is a single uncontrolled study and a programme its own developer stepped back from, not a breakthrough.
Clinical Outlook
The near-term outlook is shaped by that head start. With approved neurosteroid treatments already available, the bar for a psychedelic option in postpartum depression is high, and the most active research, perioperative ketamine and esketamine for prevention, sits somewhat apart from the psychedelic-therapy model. The genuinely novel direction is the short-acting psychedelics built for this window, but with the leading programme deprioritised and reviews still describing the area as a prospect rather than a practice[1], it is clearly early.
The realistic outlook is also bounded by an immovable safety constraint: for as long as a woman is pregnant or breastfeeding, the threshold for giving her a psychedelic is, and should be, very high. That points any eventual role toward narrow scenarios, perhaps severe, treatment-resistant postpartum depression in someone who has stopped breastfeeding, rather than broad use. The earliest serious thinking about psychedelics in this space already centres on these constraints[2]. The honest outlook is a serious but distinctly secondary line of research, in a condition that, unusually, is already getting faster help from elsewhere.
Industrial Landscape
The commercial landscape here is unusual and instructive. The companies that delivered the breakthroughs, Sage Therapeutics and Biogen with the neurosteroids brexanolone and zuranolone, are not psychedelic companies at all. Among the psychedelic developers, the most visible postpartum effort, GH Research’s inhaled 5-MeO-DMT, has been scaled back in favour of treatment-resistant depression, and others such as Reunion Neuroscience’s short-acting agent remain early. Much of the ketamine prevention work, meanwhile, comes from anaesthesia and obstetrics researchers rather than from the psychedelic field.
For an honest broker, peripartum is a useful corrective to the idea that psychedelics are the inevitable future of fast-acting psychiatry. Here a different class got there first, the psychedelic programmes are retreating or nascent, and the safety constraints around mothers and infants are genuinely binding. The responsible message is to celebrate that postpartum depression now has effective rapid treatments, to treat the perioperative-ketamine evidence as promising but unsettled, to watch the short-acting-psychedelic idea with interest and scepticism in equal measure, and to be unambiguous that this is not an area for self-experimentation, least of all during pregnancy or breastfeeding.
Quick Indicators
Related Topics
Organisations
Search →National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
MAPS
MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
Psychedelic Resource Group, Trinity College Dublin
The Psychedelic Resource Group at Trinity College Dublin advances translational psychedelic research across psychiatry and neuroscience, with a focus on clinical applications, public-health integration, and evidence generation for psychedelic-assisted care.
GH Research
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.
Washington University School of Medicine in St. Louis
The Program in Psychedelic Research (PiPer) is a partnership between The Healthy Mind Lab, the Washington University Neuroimaging Lab, and Usona Institute. PiPer leverages 30 years of neuroimaging research and four decades of psychiatry research. The group has started with four research projects around neuroimaging data in humans and animals. The university also serves as a site for Usona's Phase II/III trial with 25mg of psilocybin.
Hunan Provincial Maternal and Child Health Care Hospital
Hunan Provincial Maternal and Child Health Care Hospital is a Class-III Grade-A specialist maternity and pediatric hospital in Changsha, Hunan Province, China, founded in 1947 with over 1,050 beds and 10,000 births annually. The hospital’s anesthesiology team is a leader in esketamine obstetrics research, including a landmark BMJ randomised trial (NCT04414943) showing a single low-dose esketamine infusion after childbirth reduced major postpartum depression at 42 days by approximately three-quarters in mothers with prenatal depression.
Inonu University
İnönü University is a Turkish state research university in Malatya, with a medical faculty conducting clinical investigations across anesthesiology, psychiatry, and surgery. The university's departments have studied ketamine in obstetric anesthesia, ketamine augmentation of electroconvulsive therapy for psychiatric conditions, and cardiac safety during ECT.
Medical University Innsbruck
Leading Austrian medical university in Innsbruck. Researchers here have investigated the structural biology of psilocybin-biosynthesizing enzymes with the aim of optimizing sustainable psilocybin production, while also contributing to clinical research as European psychedelic frameworks evolve.
Peking University First Hospital
Leading academic hospital in Beijing affiliated with Peking University. Has conducted ketamine clinical trials including a randomized study of low-dose ketamine for perinatal depression, contributing to China's growing body of research on rapid-acting antidepressant therapies.
Qinghai Red Cross Hospital
Qinghai Red Cross Hospital (青海红十字医院) is a JCI-accredited 3A-grade comprehensive hospital with 2,000 beds in Xining, Qinghai Province, China, established in 1949 and the first hospital in western China to receive JCI accreditation; affiliated researchers are participating in clinical trials investigating intraoperative esketamine as a preventive treatment for postpartum depression following cesarean section.
Qinghai University
Qinghai University (青海大学) is a public comprehensive research university in Xining, Qinghai Province, China; its affiliated hospital and medical faculty are involved in clinical research investigating intraoperative esketamine as a preventive treatment for postpartum depression in women undergoing cesarean section.
The University of Texas Health Science Center at Tyler
Academic medical center in Northeast Texas and part of The University of Texas System. Conducts clinical research across pulmonary medicine, trauma, cardiology, and neurology, and has participated in trials exploring psychedelic and ketamine-assisted therapies.
People
Search →John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
James Rucker
Senior Clinical Lecturer at King's College London
Leads the Psychedelic Trials Group investigating psilocybin for treatment-resistant depression.
Theis Terwey
Co-founder of GH Research; former Chief Executive Officer
He is a co-founder and longtime leader of GH Research, the company developing GH001 and related psychedelic medicines.
Matthew Johnson
Professor of Psychiatry
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Sheng Wang
Researcher in pharmacology and structural biology (University of North Carolina at Chapel Hill, based on coauthorship on LSD/psychedelic receptor papers)
He is notable for contributing to foundational structural biology work on psychedelic receptors, including an LSD-bound human serotonin receptor structure and structure-based discovery of nonhallucinogenic psychedelic analogs.
Connected Evidence
The latest clinical data and verified academic findings associated with Peripartum.